Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardio3 rakes in new cash for heart cell therapy

This article was originally published in Clinica

Executive Summary

Belgian biotech company Cardio3 BioSciences has received €13.7m ($17.7m) in new capital to advance clinical development of its C-Cure cell-based therapy for heart failure patients. €7.2m came in the form of series B equity financing provided by Life Science Research Partners and Hunza Ventures II and Grifols, as well as other undisclosed new investors and existing Cardio3 shareholders. The remaining funds were in the form of a no-interest cash advance from the Walloon Region General Directorate for Economy, Employment and Research. Cardio3'a C-Cure technology allows a patient's own cells to be differentiated into cardiac cells that grow into new heart cells and repair heart muscle. The Mont-Saint-Guibert firm said it will shortly commence a 240-patient clinical trial of the therapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel